News | November 07, 2024
JB Pharma posts Q2 FY25 PAT 16% higher at Rs. 175 Cr
JB’s domestic business continued to out-perform the market with all our major brands posting strong growth
JB’s domestic business continued to out-perform the market with all our major brands posting strong growth
Revenue at Rs 3,623 crore, EBITDA at Rs 718 crore
The Pediatric vaccine portfolio delivered double-digit growth and maintained its market leadership in the private market
We now rank 3rd in pharmaceutical production by volume and 14th by value
At 24 months, data from the Phase 1 exPDite trial continue to show a favorable safety profile in all 12 participants in the trial’s high and low dose cohorts
Konieczny has served as Interim CEO since April 2024
Pegfilgrastim is a Pegylated form of the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue Filgrastim
Gross profit was Rs. 328.8 crore, up by 27.8% YoY with a gross margin expansion of 418 bps to 55.7%
Revenue up 16.3% to Rs 5,600 crore versus Rs 4,814 crore
Revenue from operations stood at Rs. 313.4 crore during Q1 FY25
Subscribe To Our Newsletter & Stay Updated
